Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
In the latest session, Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed at $22.22 down -2.37% from its previous closing price of $22.76. In other words, the price has decreased by -$2.37 from its previous closing price. On the day, 1.31 million shares were traded. APLS stock price reached its highest trading level at $22.645 during the session, while it also had its lowest trading level at $22.16.
Ratios:
For a deeper understanding of Apellis Pharmaceuticals Inc’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 7.55 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 636.32. For the most recent quarter (mrq), Quick Ratio is recorded 3.16 and its Current Ratio is at 3.77. In the meantime, Its Debt-to-Equity ratio is 3.01 whereas as Long-Term Debt/Eq ratio is at 2.96.
On May 09, 2025, BofA Securities Downgraded its rating to Neutral which previously was Buy but kept the price unchanged to $23.
On April 29, 2025, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $44.Cantor Fitzgerald initiated its Overweight rating on April 29, 2025, with a $44 target price.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Sep 19 ’25 when Dunlop A. Sinclair sold 31,092 shares for $22.95 per share. The transaction valued at 713,561 led to the insider holds 68,908 shares of the business.
Dunlop A. Sinclair bought 93,276 shares of APLS for $2,140,917 on Sep 19 ’25. On Sep 16 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $24.34 each. As a result, the insider received 121,700 and left with 118,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2806161664 and an Enterprise Value of 2901146880. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.72 while its Price-to-Book (P/B) ratio in mrq is 17.94. Its current Enterprise Value per Revenue stands at 3.844 whereas that against EBITDA is -15.41.
Stock Price History:
The Beta on a monthly basis for APLS is 0.69, which has changed by -0.24601287 over the last 52 weeks, in comparison to a change of 0.15101504 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -8.82%, while the 200-Day Moving Average is calculated to be -7.37%.
Shares Statistics:
For the past three months, APLS has traded an average of 2.39M shares per day and 2150180 over the past ten days. A total of 126.19M shares are outstanding, with a floating share count of 104.36M. Insiders hold about 17.39% of the company’s shares, while institutions hold 101.10% stake in the company. Shares short for APLS as of 1756425600 were 20539985 with a Short Ratio of 9.11, compared to 1753920000 on 22092024. Therefore, it implies a Short% of Shares Outstanding of 20539985 and a Short% of Float of 21.42.
Earnings Estimates
The current market rating for Apellis Pharmaceuticals Inc (APLS) reflects the collective analysis of 13.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.33, with high estimates of $0.22 and low estimates of -$0.61.
Analysts are recommending an EPS of between $0.64 and -$2.29 for the fiscal current year, implying an average EPS of -$0.4. EPS for the following year is -$1.1, with 13.0 analysts recommending between $0.49 and -$2.24.
Revenue Estimates
A total of 19 analysts believe the company’s revenue will be $372.74M this quarter.It ranges from a high estimate of $504.68M to a low estimate of $178M. As of the current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $196.83MFor the next quarter, 19 analysts are estimating revenue of $212.47M. There is a high estimate of $283M for the next quarter, whereas the lowest estimate is $182.1M.
A total of 20 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.04B, while the lowest revenue estimate was $705.4M, resulting in an average revenue estimate of $935.42M. In the same quarter a year ago, actual revenue was $781.37MBased on 20 analysts’ estimates, the company’s revenue will be $906.84M in the next fiscal year. The high estimate is $1.02B and the low estimate is $757.8M.
